Skip to main content
SpringerLink
Log in

Transcatheter Mitral Valve Replacement: An Update on the Current Literature

  • Valvular Heart Disease (J Dal-Bianco, Section Editor)
  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Abstract

Purpose of review

The purpose of this review was to evaluate the complexities and challenges associated with transcatheter mitral valve replacement and review the existing data.

Recent findings

Many patients with mitral valve disease are not candidates for cardiac surgery and are in need of less invasive transcatheter therapies. The first transcatheter mitral valve replacement (TMVR) in a native valve was performed in 2012. However, the complexities and variability of the mitral valve anatomy and its relationship to neighboring structures have resulted in slower progress with this new therapy compared to the rapid uptake that has occurred with transcatheter aortic valve replacement. TMVR can be applied to degenerated prosthetic valves and annuloplasty rings or to a wide variety of native mitral valve disease. In cases of degenerated bioprosthetic valves, annuloplasty ring, and native valve mitral annular calcification, transcatheter heart valves (THVs) designed for the aortic position can be implanted with high procedural safety and success rates. In the case of native valve mitral regurgitation, the complexities have led to the development of several TMVR systems for native valve disease with different anchoring mechanisms and geometry; all are currently investigational and none are FDA approved at this time. It is clear from the initial experience with TMVR that careful patient selection and pre-procedural planning are necessary to maximize benefit and avoid complications.

Summary

TMVR is an exciting complex therapy offering promise for patients who cannot be treated with existing techniques. The key to success will be a combination of appropriate patient selection, careful comprehensive pre-procedural planning, rising new technologies, as well as further research to appropriately define and mitigate the risks associated with the procedure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Mirabel M, et al. What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? Eur Heart J. 2007;28(11):1358–65.

    Article  Google Scholar 

  2. Goel SS, Bajaj N, Aggarwal B, Gupta S, Poddar KL, Ige M, et al. Prevalence and outcomes of unoperated patients with severe symptomatic mitral regurgitation and heart failure: comprehensive analysis to determine the potential role of MitraClip for this unmet need. J Am Coll Cardiol. 2014;63(2):185–6.

    Article  Google Scholar 

  3. Nishimura RA, et al. Mitral valve disease—current management and future challenges. Lancet. 2016;387(10025):1324–34.

    Article  Google Scholar 

  4. Stone GW, Lindenfeld JA, Abraham WT, Kar S, Lim DS, Mishell JM, et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med. 2018;379(24):2307–18.The COAPT trial which demonstrated reduction in mortality and rehospitalization with transcatheter treatment of severe secondary mitral regurgitation.

    Article  Google Scholar 

  5. Pibarot P, Dumesnil JG. Prosthetic heart valves: selection of the optimal prosthesis and long-term management. Circulation. 2009;119(7):1034–48.

    Article  Google Scholar 

  6. Bouleti C, et al. Transfemoral implantation of transcatheter heart valves after deterioration of mitral bioprosthesis or previous ring annuloplasty. JACC Cardiovasc Interv. 2015;8(1 Pt A):83–91.

    Article  Google Scholar 

  7. Ye J, Cheung A, Yamashita M, Wood D, Peng D, Gao M, et al. Transcatheter aortic and mitral valve-in-valve implantation for failed surgical bioprosthetic valves: an 8-year single-center experience. JACC Cardiovasc Interv. 2015;8(13):1735–44.

    Article  Google Scholar 

  8. Yoon SH, et al. Transcatheter mitral valve replacement for degenerated bioprosthetic valves and failed annuloplasty rings. J Am Coll Cardiol. 2017;70(9):1121–31.

    Article  Google Scholar 

  9. Eleid MF, et al. Early outcomes of percutaneous transvenous transseptal transcatheter valve implantation in failed bioprosthetic mitral valves, ring annuloplasty, and severe mitral annular calcification. JACC Cardiovasc Interv. 2017;10(19):1932–42.

    Article  Google Scholar 

  10. Guerrero M, Wang DD, Himbert D, Urena M, Pursnani A, Kaddissi G, et al. Short-term results of alcohol septal ablation as a bail-out strategy to treat severe left ventricular outflow tract obstruction after transcatheter mitral valve replacement in patients with severe mitral annular calcification. Catheter Cardiovasc Interv. 2017;90(7):1220–6.

    Article  Google Scholar 

  11. Babaliaros VC, et al. Intentional percutaneous laceration of the anterior mitral leaflet to prevent outflow obstruction during transcatheter mitral valve replacement: first-in-human experience. JACC Cardiovasc Interv. 2017;10(8):798–809.Studies of novel techniques to predict and manage left ventricular outflow tract obstruction.

  12. Guerrero M, et al. 1-year outcomes of transcatheter mitral valve replacement in patients with severe mitral annular calcification. J Am Coll Cardiol. 2018;71(17):1841–53.Initial pioneering studies of transseptal and transapical balloon-expandable mitral valve implantation.

  13. Yoon SH, Whisenant BK, Bleiziffer S, Delgado V, Dhoble A, Schofer N, et al. Outcomes of transcatheter mitral valve replacement for degenerated bioprostheses, failed annuloplasty rings, and mitral annular calcification. Eur Heart J. 2019;40(5):441–51.Initial pioneering studies of transseptal and transapical balloon-expandable mitral valve implantation.

  14. Yoon SH, et al. Predictors of left ventricular outflow tract obstruction after Transcatheter mitral valve replacement. JACC Cardiovasc Interv. 2019;12(2):182–93.Initial pioneering studies of transseptal and transapical balloon-expandable mitral valve implantation.

  15. Sondergaard L, et al. First-in-human case of transfemoral CardiAQ mitral valve implantation. Circ Cardiovasc Interv. 2015;8(7):e002135.

    Article  Google Scholar 

  16. Cheung A, et al. Short-term results of transapical transcatheter mitral valve implantation for mitral regurgitation. J Am Coll Cardiol. 2014;64(17):1814–9.

    Article  Google Scholar 

  17. Cheung A, et al. Transcatheter mitral valve replacement in patients with previous aortic valve replacement. Circ Cardiovasc Interv. 2018;11(10):e006412.

    Article  Google Scholar 

  18. Meredith I, Bapat V, Morriss J, McLean M, Prendergast B. Intrepid transcatheter mitral valve replacement system: technical and product description. EuroIntervention. 2016;12(Y):Y78–80.

    Article  Google Scholar 

  19. Bapat V, et al. Early experience with new transcatheter mitral valve replacement. J Am Coll Cardiol. 2018;71(1):12–21.

    Article  Google Scholar 

  20. Perpetua EM, Reisman M. The Tendyne transcatheter mitral valve implantation system. EuroIntervention. 2015;11(Suppl W):W78-9.

    PubMed  Google Scholar 

  21. Muller DWM, et al. The Tendyne early feasibility trial of transcatheter mitral valve implantation. J Am Coll Cardiol. 2016;67(13):32.Largest reports of the early clinical experience with dedicated TMVR devices.

    Article  Google Scholar 

  22. Barbanti M, et al. Transcatheter mitral valve implantation using the HighLife system. JACC Cardiovasc Interv. 2017;10(16):1662–70.

    Article  Google Scholar 

  23. Lange R. A two-component, self-centering TMV system. Paper presented at: Transcatheter Cardiovascular Therapeutics (TCT), October 31, 2016, Washington, DC. Available at: https://www.tctmd.com/slide/highlife-design-and-clinical-trialupdates.

  24. Makkar R. SAPIEN M3 Transcatheter Mitral valve replacement system: 30-day outcomes from the US early feasibility study. Paper presented at: Transcatheter Cardiovascular Therapeutics (TCT), September 24, 2018, San Diego, CA. Available at: https://www.tctmd.com/slide/sapien-m3-transcatheter-mitral-valve-replacement-system-30-day-outcomes-us-early-feasibility.

  25. Nunes Ferreira-Neto A, Dagenais F, Bernier M, Dumont E, Freitas-Ferraz AB, Rodés-Cabau J. Transcatheter mitral valve replacement with a new supra-annular valve: first-in-human experience with the AltaValve System. JACC Cardiovasc Interv. 2019;12(2):208–9.

    Article  Google Scholar 

  26. Cheung A, et al. 5-year experience with transcatheter transapical mitral valve-in-valve implantation for bioprosthetic valve dysfunction. J Am Coll Cardiol. 2013;61(17):1759–66.

    Article  Google Scholar 

  27. Eleid MF, Cabalka AK, Williams MR, Whisenant BK, Alli OO, Fam N, et al. Percutaneous transvenous transseptal transcatheter valve implantation in failed bioprosthetic mitral valves, ring annuloplasty, and severe mitral annular calcification. JACC Cardiovasc Interv. 2016;9(11):1161–74.Initial pioneering studies of transseptal and transapical balloon-expandable mitral valve implantation.

    PubMed  Google Scholar 

  28. Guerrero M, Dvir D, Himbert D, Urena M, Eleid M, Wang DD, et al. Transcatheter mitral valve replacement in native mitral valve disease with severe mitral annular calcification: results from the first multicenter global registry. JACC Cardiovasc Interv. 2016;9(13):1361–71.

    Article  Google Scholar 

  29. Wang DD, Eng MH, Greenbaum AB, Myers E, Forbes M, Karabon P, et al. Validating a prediction modeling tool for left ventricular outflow tract (LVOT) obstruction after transcatheter mitral valve replacement (TMVR). Catheter Cardiovasc Interv. 2018;92(2):379–87.

    Article  Google Scholar 

  30. Guerrero M, Eleid M, Foley T, Said S, Rihal C. Transseptal transcatheter mitral valve replacement in severe mitral annular calcification (transseptal valve-in-MAC). Ann Cardiothorac Surg. 2018;7(6):830–3.

    Article  Google Scholar 

  31. Wang DD, et al. Pre-emptive alcohol septal ablation to prevent left ventricular outflow tract obstruction during transcatheter mitral valve replacement: early clinical experience in a multi-center, observational first-in-man study. JACC Cardiovasc Interv. 2019 [in press].Studies of novel techniques to predict and manage left ventricular outflow tract obstruction.

  32. Ussia GP, et al. Percutaneous transfemoral-transseptal implantation of a second-generation CardiAQ mitral valve bioprosthesis: first procedure description and 30-day follow-up. EuroIntervention. 2016;11(10):1126–31.

    Article  Google Scholar 

  33. Verheye S, Cheung A, Leon M, Banai S. The Tiara transcatheter mitral valve implantation system. EuroIntervention. 2015;11(Suppl W):W71-2.

    PubMed  Google Scholar 

  34. Quarto C, et al. Transcatheter mitral valve implantation: 30-day outcome of first-in-man experience with an apically tethered device. Innovations (Phila). 2016;11(3):174–8.

    Article  Google Scholar 

  35. Muller DWM, Farivar RS, Jansz P, Bae R, Walters D, Clarke A, et al. Transcatheter mitral valve replacement for patients with symptomatic mitral regurgitation: a global feasibility trial. J Am Coll Cardiol. 2017;69(4):381–91.

    Article  Google Scholar 

  36. Sorajja P, Bapat V. Early experience with the Intrepid system for transcatheter mitral valve replacement. Ann Cardiothorac Surg. 2018;7(6):792–8.Largest reports of the early clinical experience with dedicated TMVR devices.

    Article  Google Scholar 

  37. Navia JL, Kapadia S, Elgharably H, Harb SC, Krishnaswamy A, Unai S, et al. First-in-human implantations of the NaviGate bioprosthesis in a severely dilated tricuspid annulus and in a failed tricuspid annuloplasty ring. Circ Cardiovasc Interv. 2017;10(12).

  38. Sondergaard L, Ussia GP, Dumonteil N, Quadri A. The CardiAQ transcatheter mitral valve implantation system. EuroIntervention. 2015;11(Suppl W):W76-7.

    PubMed  Google Scholar 

  39. Regueiro A, et al. 2-year outcomes after transcatheter mitral valve replacement. JACC Cardiovasc Interv. 2017;10(16):1671–8.

    Article  Google Scholar 

  40. Regueiro A, et al. Transcatheter mitral valve replacement: insights from early clinical experience and future challenges. J Am Coll Cardiol. 2017;69(17):2175–92.

  41. Muller D. CE mark study of transcatheter mitral valve replacement for severe mitral regurgitation: 30-day outcomes of the first 100 patients. Paper presented at: EuroPCR, Paris, May 25, 2018. http://www.tctmd.com/slide/ce-mark-study-transcatheter-mitral-valve-replacement- severe-mitral-regurgitation-30-day.

  42. Niikura H, et al. Causes and clinical outcomes of patients who are ineligible for transcatheter mitral valve replacement. JACC Cardiovasc Interv. 2019;12(2):196–204.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiovascular Medicine Mayo Clinic, Rochester, MN, USA

    Stephanie C. El Hajj MD & Mackram F. Eleid MD

Authors
  1. Stephanie C. El Hajj MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mackram F. Eleid MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mackram F. Eleid MD.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Valvular Heart Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

El Hajj, S.C., Eleid, M.F. Transcatheter Mitral Valve Replacement: An Update on the Current Literature. Curr Treat Options Cardio Med 21, 35 (2019). https://doi.org/10.1007/s11936-019-0734-3

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11936-019-0734-3

Keywords

Search

Navigation